On the Management of Metastatic Prostate Cancer with LH-RH Analogs
With the availability of luteinizing hormone releasing hormone (LH-RH) agonists, and in the future of maybe also of LH-RH antagonists, new principles were introduced into the clinical management of human prostate carcinoma and other steroid-hormone-dependent tumors (Schröder et al. 1987). LH-RH agonists offered a new principle of suppressing testicular androgen to castration levels, the major advantage of which over the classical forms of treatment with estrogen administration or castration seemed to be an absence of physical side effects and a reduction of physiological side effects. For these advantages a much higher price has to be paid, and it now remains questionable in how far LH-RH agonists will be able to compete with other principles of castration in the management of this disease.
KeywordsAdvanced Prostate Cancer Metastatic Prostate Cancer Plasma Testosterone Luteinizing Hormone Release Hormone LHRH Agonist
Unable to display preview. Download preview PDF.
- Blom JHM, Hirdes WH, Schröder FH, De Jong FH, Kwekkeboom DJ, van Veen AJ, Sandow J, Krauss B (1989) Pharmacokinetics and endocrine effects of the LHRH analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients. Urol Res 17:43–46PubMedCrossRefGoogle Scholar
- Brisset J-M, Boccon-Gibod L, Botto H, Camey M, Cariou G, Duclos J-M, Duval F, Gonties D, Jorest R, Lamy L, LeDuc A, Mouton A, Petit M, Prawerman A, Richard F, Sava-tovsky I, Vallancie G (1987) Anandron (RU 23908) associated to surgical castration in previously untreated stage D prostate cancer: a multicenter comparative study of two doses of the drug and of a placebo. In: Khoury S, Murphy GP (eds) Cancer of the prostate. Liss, New YorkGoogle Scholar
- Denis L, Keuppens F, Robinson M, Mahler C, Smith P, Pinto de Carvalho APA, Newling D, Bono A, Sylvester R, De Pauw M, Vermeylen K, Ongena P and members of the EORTC GU group (1990) Complete androgen blockade: data from an EORTC 30853 trial. Sem Urol 8:166–174Google Scholar
- Iversen P, Christensen MG, Friis E, Hornbol P, Hvidt V, Iversen HG, Klarskov P, Kramp T, Lund F, Mogensen P, Pedersen T, Rasmussen F, Rose C, Skaarup P, Wolf H (1990) A phase III trial of Zoladex and Flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate. Cancer 66:1058–1066PubMedGoogle Scholar
- Kuhn J-M, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis J-F, Costa P, Husson J-M, Dahan R, Bertagna C, Edelstein R (1989) Prevention of the transient edverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 321:413–418PubMedCrossRefGoogle Scholar
- Labrie F, Dupont A, Belanger A, Lacoursiere Y, Raynaud JP, Husson JM, Gareau J, Fazekas ATA, Sandow J, Monfette G, Girard JG, Emond J, Houle JG (1983) New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 4:579–594PubMedCrossRefGoogle Scholar
- Navratil H (1987) Double-blind study of Anandron versus placebo in Stage D2 prostate cancer patients receiving buserelin. Results in 49 cases from a multicentre study. In: Khoury S, Murphy GP (eds) Cancer of the prostate. Liss, New YorkGoogle Scholar
- Schröder FH, Lock TMTW, Chadha DR, Debruyne FMJ, Karthaus HFM, De Jong FH, Klijn JGM, Matroos AW, De Voogt HJ (1987) Metastatic cancer of the prostate managed with buserelin versus buserelin plus cyproterone acatate. J Urol 137:912–918Google Scholar
- Waxman J, Williams G, Sandow J, Hewitt G, Abel P, Farah N, Fleming J, Cox J, O’Donoghue EPN, Sikora K (1988) The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-re-leasing hormone analogue. Am J Clin Oncol 11 [Suppl 2]:S152–S155PubMedCrossRefGoogle Scholar